PA
PCVX icon

Parallel Advisors’s Vaxcyte PCVX Stock Holding History

Parallel Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
2,260
+566
+33% +$30.7K ﹤0.01% 1522
2026
Q1 		$98.4K Buy
1,694
+1,108
+189% +$60.2K ﹤0.01% 1596
2025
Q4 		$27K Sell
586
-594
-50% -$26.6K ﹤0.01% 2150
2025
Q3 		$42.5K Sell
1,180
-729
-38% -$24.2K ﹤0.01% 1867
2025
Q2 		$62.1K Buy
1,909
+312
+20% +$10.2K ﹤0.01% 1602
2025
Q1 		$61K Buy
1,597
+1,071
+204% +$85.6K ﹤0.01% 1519
2024
Q4 		$43.1K Buy
526
+9
+2% +$894 ﹤0.01% 1723
2024
Q3 		$59.1K Buy
517
+50
+11% +$4.51K ﹤0.01% 1523
2024
Q2 		$35.3K Buy
467
+14
+3% +$953 ﹤0.01% 1704
2024
Q1 		$30.9K Buy
453
+42
+10% +$2.91K ﹤0.01% 1740
2023
Q4 		$25.8K Buy
411
+250
+155% +$13K ﹤0.01% 1785
2023
Q3 		$8.21K Buy
161
+140
+667% +$6.91K ﹤0.01% 2290
2023
Q2 		$1.05K Hold
21
– – ﹤0.01% 2916
2023
Q1 		$787 Sell
21
-6
-22% -$255 ﹤0.01% 3011
2022
Q4 		$1.29K Buy
27
+16
+145% +$628 ﹤0.01% 2832
2022
Q3 		$0 Buy
+11
New +$279 ﹤0.01% 3404
2021
Q4 		– Sell
-28
Closed -$1K – 3237
2021
Q3 		$1K Buy
+28
New +$679 ﹤0.01% 2927

Other funds holding PCVX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallel Advisors's PCVX Position: Q2 2026 in Review

Parallel Advisors increased its Vaxcyte (PCVX) stake by 33% in Q2 2026, buying an estimated $30.7K and bringing the position to 2,260 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

Parallel Advisors first reported a position in PCVX in Q3 2021 and has held it in 17 quarters since. 222 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Parallel Advisors held 2,260 shares of Vaxcyte worth $131K as of Q2 2026.
  • Parallel Advisors bought 566 Vaxcyte shares in Q2 2026, an estimated $30.7K.
  • Vaxcyte made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1522 holding.
  • Parallel Advisors first reported a position in Vaxcyte in Q3 2021 and has held it in 17 quarters since.
  • 222 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.